The generic name of Trulicity is dulaglutide. It is a once-weekly injectable GLP-1 receptor agonist used for type 2 diabetes, manufactured by Eli Lilly and FDA-approved in 2014. No generic or biosimilar version of dulaglutide is available in the United States as of 2026 — Eli Lilly’s patent extends into 2027, and complex biologic manufacturing barriers mean follow-on versions are likely to take additional years to reach the market.
What Dulaglutide Is
Dulaglutide is a recombinant fusion protein created by joining two parts:
- A modified version of the natural human GLP-1 hormone — with specific amino acid substitutions that make it resistant to enzymatic breakdown
- A human IgG4 immunoglobulin Fc fragment — which dramatically extends the molecule’s circulation time
The two pieces are linked by a flexible peptide linker. Each Trulicity dose contains two GLP-1 molecules attached to one Fc fragment. The IgG4 Fc portion is what gives dulaglutide its long half-life of about 5 days, supporting once-weekly subcutaneous dosing.
How Dulaglutide Works
GLP-1 (glucagon-like peptide-1) is a natural incretin hormone released by intestinal L cells in response to food. It has multiple effects that improve glucose control. Dulaglutide mimics these effects:
- Enhances glucose-dependent insulin secretion from pancreatic beta cells
- Suppresses inappropriate glucagon release from pancreatic alpha cells
- Slows gastric emptying, which blunts post-meal glucose rises
- Acts on appetite centers in the hypothalamus to reduce hunger and food intake
- May improve beta-cell function over time
Because the insulin effect is glucose-dependent, dulaglutide does not cause hypoglycemia on its own — risk rises only when combined with insulin or sulfonylureas.
Trulicity at a Glance
| Feature | Detail |
|---|---|
| Brand name | Trulicity |
| Generic name | Dulaglutide |
| Drug class | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly and Company |
| FDA approval year | 2014 (type 2 diabetes) |
| CV indication | Reduce MACE in T2D with established CV disease or multiple CV risk factors (2020) |
| Available doses | 0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg per week |
| Route | Subcutaneous injection (single-use pen) |
| Frequency | Once weekly |
| Half-life | ~5 days |
| Generic available | No (US, as of 2026) |
| Patent expiry | 2027 (main US patent) |
| Typical monthly retail cost (US) | ~$900–$1,100 |
Why No Generic Trulicity Exists Yet
Three factors keep dulaglutide branded-only as of 2026:
- The primary US composition-of-matter patent extends into 2027
- Additional formulation and use patents may extend protection further
- Even after patent expiry, dulaglutide is a biologic — generic copies would need to be approved as biosimilars rather than small-molecule generics, which requires extensive characterization studies, clinical trials, and specialized manufacturing capability
For comparison, the first biosimilar insulin glargine (Basaglar) reached the US market in 2016, about 16 years after the original Lantus approval. Biosimilars for GLP-1 receptor agonists are expected but the exact timeline remains uncertain. Currently no biosimilar GLP-1 receptor agonist has been approved in the US.
Approved Indications
- Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes
- To reduce major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors — approved based on the REWIND trial
Dulaglutide is not approved for weight loss alone (semaglutide as Wegovy, liraglutide as Saxenda, and tirzepatide as Zepbound carry weight loss indications); it is not approved for type 1 diabetes; and it is not approved for diabetic ketoacidosis.
Dose Escalation
| Step | Dose | When to Adjust |
|---|---|---|
| Start | 0.75 mg weekly | For 4 weeks, then assess |
| Step 2 | 1.5 mg weekly | If 0.75 mg tolerated; A1C reassessed in 4 weeks |
| Step 3 | 3.0 mg weekly | If 1.5 mg insufficient and tolerated for at least 4 weeks |
| Step 4 (max) | 4.5 mg weekly | If 3.0 mg insufficient and tolerated for at least 4 weeks |
Effectiveness
Across the AWARD trial program, dulaglutide reduces A1C by approximately 1.0 to 1.6 percent depending on dose, baseline A1C, and concurrent therapy. Average weight loss is 2 to 4 kg, with the 3.0 mg and 4.5 mg doses producing slightly more weight loss than the 1.5 mg dose.
The REWIND trial (Gerstein et al., Lancet 2019) randomized 9,901 adults with type 2 diabetes to dulaglutide 1.5 mg or placebo. Over a median 5.4 years, dulaglutide reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 12 percent. This was the first cardiovascular outcomes trial to show benefit in a population that included many patients without established cardiovascular disease.
Common Side Effects
- Nausea (in roughly 12 to 21 percent of users, more common during dose escalation)
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
- Constipation
- Indigestion
- Fatigue (less common)
- Injection site reactions (mild and infrequent)
Serious Risks and Contraindications
- Boxed warning: thyroid C-cell tumors — based on rodent data; risk in humans is unclear
- Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Pancreatitis — uncommon; discontinue if pancreatitis is suspected
- Acute kidney injury — usually in the setting of severe nausea, vomiting, dehydration
- Gallbladder disease — gallstones and cholecystitis reported
- Hypoglycemia when combined with insulin or sulfonylureas
- Severe gastrointestinal disease — caution with severe gastroparesis
- Hypersensitivity reactions (rare)
- Diabetic retinopathy complications — monitor in patients with pre-existing retinopathy
Comparison with Other GLP-1 Receptor Agonists
| Generic | Brand | Frequency | Doses | Notable Features |
|---|---|---|---|---|
| Dulaglutide | Trulicity | Weekly SC | 0.75–4.5 mg | IgG4 fusion; long half-life; CV outcomes data |
| Semaglutide | Ozempic (T2D), Wegovy (obesity) | Weekly SC | 0.25–2.4 mg | Fatty-acid modified peptide; large CV and weight loss data |
| Semaglutide (oral) | Rybelsus | Daily oral | 3, 7, 14 mg | Co-formulated with SNAC absorption enhancer |
| Liraglutide | Victoza (T2D), Saxenda (obesity) | Daily SC | 0.6–1.8 mg (T2D); up to 3.0 mg (obesity) | Albumin binding; shorter half-life (~13 hr) |
| Exenatide | Byetta, Bydureon BCise | Twice daily or weekly SC | 5–10 mcg BID or 2 mg weekly | From Gila monster venom (exendin-4) |
| Lixisenatide | Adlyxin | Daily SC | 10–20 mcg | Short-acting; mostly post-prandial effect |
To clarify the relationship between dulaglutide and semaglutide, see our piece on is Trulicity a semaglutide. For class-level detail, see Trulicity class.
Storage and Handling
- Store unused pens in the refrigerator (36 to 46 degrees F / 2 to 8 degrees C)
- Each pen can be kept at room temperature (below 86 degrees F / 30 degrees C) for up to 14 days if needed
- Do not freeze — discard if frozen
- Protect from light
- Each pen is single-use; dispose of in a sharps container
- Inspect the solution: it should be clear and colorless; do not use if cloudy, discolored, or contains particles
Cost and Coverage
Without insurance, Trulicity retail prices in the US are typically 900 to 1,100 dollars per month. With commercial insurance, copays range from 25 to 200 dollars per month. The Eli Lilly manufacturer savings card can reduce out-of-pocket costs for eligible patients. Medicare Part D coverage varies by plan. People in the donut hole or without insurance may face the full retail cost.
Until a biosimilar reaches the market, Trulicity remains the only source of dulaglutide. Alternative GLP-1 receptor agonists (semaglutide, liraglutide) are similarly priced and similarly branded-only.
What to Do If Cost Is a Barrier
- Ask the prescriber to check eligibility for the Eli Lilly Trulicity Savings Card
- Apply to the Lilly Cares Foundation patient assistance program if uninsured or underinsured
- Compare GLP-1 options — coverage and copay can differ widely by insurance formulary
- Discuss whether an alternative class (DPP-4 inhibitor, SGLT2 inhibitor) makes sense if cost is prohibitive
- See our piece on alternative to metformin for broader options
Talking to Your Clinician
Useful questions:
- What dose are we targeting and over what timeline?
- How will we measure success — A1C, weight, blood pressure?
- What side effects should I expect during dose escalation?
- How does Trulicity fit with my other medications?
- What is my out-of-pocket cost and is there a savings card available?
- Are there reasons a different GLP-1 agonist would be better for me?
For background on A1C targets, see our A1C levels guide.
The Bottom Line
The generic name of Trulicity is dulaglutide. It is a once-weekly GLP-1 receptor agonist used for type 2 diabetes, with proven cardiovascular benefits from the REWIND trial. No generic or biosimilar dulaglutide is available in the United States as of 2026 — the patent extends into 2027 and biologic biosimilars face complex regulatory and manufacturing pathways that often add years before market entry. Dulaglutide is one of several GLP-1 receptor agonists; it is not the same drug as semaglutide, liraglutide, exenatide, or lixisenatide, though they all act on the same receptor. Talk with your clinician about whether dulaglutide is the right GLP-1 choice for your situation and whether manufacturer savings programs can reduce out-of-pocket cost.
